Prader-Willi Syndrome
SunTrust said it hasn't changed its benefit-risk profile for Zafgen Inc (NASDAQ: ZFGN)'s beloranib, citing that thromboembolic risks linger on the obesity drug that showed statistically and clinically significant improvements in body weight and glycemic control in a mid-stage trial. Related Link:... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to:
Source: benzinga.com